Gastrointestinal perforation

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients

Retrieved on: 
Monday, December 11, 2023

Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.

Key Points: 
  • Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.
  • Gastrointestinal Perforations and Fistula: Discontinue for gastrointestinal perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ.
  • Surgery and Wound Healing Complications: In patients who experience wound healing complications during VEGZELMA treatment, withhold VEGZELMA until adequate wound healing.
  • Do not administer VEGZELMA for at least 28 days following a major surgery, and until adequate wound healing.

Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States

Retrieved on: 
Monday, October 3, 2022

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced the commercial launch of ALYMSYS (bevacizumab-maly), a biosimilar referencing Avastin.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced the commercial launch of ALYMSYS (bevacizumab-maly), a biosimilar referencing Avastin.
  • The launch of ALYMSYS provides additional access and choice to affordable oncology therapeutics for providers and patients.
  • Amneal has officially entered the U.S. biosimilar market.
  • We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States.